Retrieve available abstracts of 8 articles: HTML format
Single Articles
December 2025
THIERENS N, Verdonk RC, Lohr JM, van Santvoort HC, et al Chronic pancreatitis.
Lancet. 2025;404:2605-2618. PubMedAbstract available
April 2025
STOOP TF, Javed AA, Oba A, Koerkamp BG, et al Pancreatic cancer.
Lancet. 2025;405:1182-1202. PubMedAbstract available
April 2024
MAITRA A, Topol EJ Early detection of pancreatic cancer and AI risk partitioning.
Lancet. 2024;403:1438. PubMed
January 2024
KAIMAKLIOTIS PI, Kochman ML Prophylactic pancreatic stent placement to prevent pancreatitis after ERCP.
Lancet. 2024 Jan 11:S0140-6736(23)02719-8. doi: 10.1016/S0140-6736(23)02719. PubMed
ELMUNZER BJ, Foster LD, Serrano J, Cote GA, et al Indomethacin with or without prophylactic pancreatic stent placement to prevent
pancreatitis after ERCP: a randomised non-inferiority trial.
Lancet. 2024 Jan 11:S0140-6736(23)02356-5. doi: 10.1016/S0140-6736(23)02356. PubMedAbstract available
December 2023
WANG S, Wang Y, Zhang Z, Lu W, et al Acute pancreatitis as a key to diagnosis of hyperhomocysteinemia in a 12-year-old
boy caused by CBS gene mutation.
Lancet. 2023;402:2235-2236. PubMed
September 2023
BESSELINK MG, Wilmink JW Treating metastatic pancreatic ductal adenocarcinoma: NALIRIFOX as new standard?
Lancet. 2023 Sep 11:S0140-6736(23)01521-0. doi: 10.1016/S0140-6736(23)01521. PubMed
WAINBERG ZA, Melisi D, Macarulla T, Pazo Cid R, et al NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with
metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label,
phase 3 trial.
Lancet. 2023 Sep 11:S0140-6736(23)01366-1. doi: 10.1016/S0140-6736(23)01366. PubMedAbstract available